Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer
- PMID: 31051242
- DOI: 10.1016/j.jsbmb.2019.04.016
Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer
Abstract
Sex-steroid hormones have been investigated for decades for their oncogenic properties in hormone-dependent cancers. The increasing body of knowledge on the biological actions of androgens in prostate cancer has led to the development of several targeted therapies that still represent the standard of care for cancer patients to this day. In the prostate, androgens promote cellular differentiation and proper tissue development. These hormones also promote the aberrant proliferation and survival of prostate cancer cells. Over the past few years, sequencing technologies for functional genomic analyses have rapidly expanded, revealing novel functions of sex-steroid hormone receptors other than their classic roles. In this article, we will focus on transcriptomic- and genomic-based evidence that demonstrates the importance of the androgen receptor signaling in the regulation of prostate cancer cell metabolism. This is significant because the reprogramming of cell metabolism is a hallmark of cancer. In fact, it is clear now that the androgen receptor contributes to the reprogramming of specific cellular metabolic pathways that promote tumor growth and disease progression, including aerobic glycolysis, mitochondrial respiration, fatty acid ß-oxidation, and de novo lipid synthesis. Overall, beyond regulating development, differentiation, and proliferation, the androgen receptor is also a master regulator of cellular energy metabolism.
Keywords: Androgen; Castration-resistant prostate cancer; Estrogen; Metabolomics; Prostate; Steroid.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.Genes Dev. 2017 Jun 15;31(12):1228-1242. doi: 10.1101/gad.299958.117. Epub 2017 Jul 19. Genes Dev. 2017. PMID: 28724614 Free PMC article.
-
Androgen action in the prostate gland.Minerva Urol Nefrol. 2012 Mar;64(1):35-49. Minerva Urol Nefrol. 2012. PMID: 22402316 Review.
-
Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. BJU Int. 2009. PMID: 19558559 Review.
-
Metabolic Roles of Androgen Receptor and Tip60 in Androgen-Dependent Prostate Cancer.Int J Mol Sci. 2020 Sep 10;21(18):6622. doi: 10.3390/ijms21186622. Int J Mol Sci. 2020. PMID: 32927797 Free PMC article. Review.
-
Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.Oncotarget. 2015 Oct 13;6(31):31997-2012. doi: 10.18632/oncotarget.5585. Oncotarget. 2015. PMID: 26378018 Free PMC article.
Cited by
-
Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.Cancer Med. 2023 Jan;12(1):862-878. doi: 10.1002/cam4.4856. Epub 2022 Jun 9. Cancer Med. 2023. PMID: 35681277 Free PMC article.
-
A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.Elife. 2021 Aug 12;10:e62592. doi: 10.7554/eLife.62592. Elife. 2021. PMID: 34382934 Free PMC article.
-
Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression.Oncogene. 2021 Nov;40(47):6479-6493. doi: 10.1038/s41388-021-02026-7. Epub 2021 Oct 5. Oncogene. 2021. PMID: 34611310
-
Receptor-Mediated Redox Imbalance: An Emerging Clinical Avenue against Aggressive Cancers.Biomolecules. 2022 Dec 15;12(12):1880. doi: 10.3390/biom12121880. Biomolecules. 2022. PMID: 36551308 Free PMC article. Review.
-
Knockdown of OLR1 weakens glycolytic metabolism to repress colon cancer cell proliferation and chemoresistance by downregulating SULT2B1 via c-MYC.Cell Death Dis. 2021 Dec 17;13(1):4. doi: 10.1038/s41419-021-04174-w. Cell Death Dis. 2021. PMID: 34921134 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
